Albireo Pharma, Inc. ALBO Cash Flow

Albireo pharma, inc. (ALBO)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11
Cash flows from operating activities:
Net loss
-77,548	-62,717	-71,059	-63,174	-61,149	-46,111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-19,782	-16,350	-8,345	-7,547	-16,148	-17,265	-18,737	-17,791	-14,534	-16,375	-14,131	-12,660	-19,086	-18,109	-19,335	-24,399	-20,818	-19,915	-20,747	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of liability related to sale of future royalties
8,395	8,360	8,274	9,022	7,973	6,975	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of debt discount and amortization of issuance costs
-	-	-	-	-	-	-	-	-	163	608	809	959	1,065	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
155	127	101	73	3	45	45	44	83	35	26	20	15	14	41	23	67	125	197	352	457	549	603	619	625	630	641	654	669	698	725	0	0	0
Change in fair value of financial instruments
-	-	-	-	-	-	-	-	-	251	-272	-356	-231	13	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Founder's compensation contributed to capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Stock-based compensation expense
8,136	7,578	7,376	7,174	6,181	5,546	4,707	3,893	3,483	3,700	3,805	3,134	2,133	1,138	305	383	964	784	868	790	700	684	784	967	1,157	1,288	1,538	1,533	1,539	1,531	1,828	0	0	0
Unrealized foreign exchange loss
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency adjustments
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Trade receivables
-	-	-	-	-	-	-	-	-	-28	1	-25	-1,706	-1,246	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation for non-employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Loss on settlement of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Write-off of capitalized patent expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38	38	38	0	0	0
Write-off of loan to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Adjustments to fair value of common stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	176	299	465	1,009	2,230	3,658	3,067	5,107	7,244	1,266	1,575	1,217	-2,475	601	863	-1,510	0	0	0
Prepaid expenses and other current assets
4,722	6,331	2,843	2,389	2,831	2,104	1,831	1,938	74	467	271	418	309	214	104	-14	-60	-227	-51	-15	10	165	47	-294	-343	-391	-31	272	326	289	-111	0	0	0
Other receivables
-	-	-	-	-	-	-	-	777	339	487	304	426	142	0	0	0	-	-	-	-	-	-	-	-	-	-8	1	1	0	8	0	0	0
Other assets
-215	360	214	365	369	-403	-119	-121	-164	245	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-28	-16	-1	-1	-1	0	0	0
Grant receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26	202	178	-188	-63	24	28	284	88	0	0	0
Accounts payable
4,072	577	0	0	0	-	-	-	-	-	-	-	-	-	-271	278	-231	-100	249	-185	-295	-1,353	-74	134	329	659	-39	60	198	978	63	0	0	0
Trade payables
-	-	-	-	-	-	-	-	853	263	171	-69	-1,546	-1,164	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	16	-4	-1	-75	-75	-90	-90	-26	0	0	-12	-2	0	0	0
Accrued expenses
-9,463	-4,095	-27	805	816	854	23	-64	337	-1,705	-1,638	-2,765	-552	3,214	1,282	0	0	0	-	725	545	10	-703	-711	-470	-1,817	-247	-451	-1,064	398	-128	0	0	0
Other current and long-term liabilities
459	-64	-214	-260	-628	-198	3	314	344	273	269	196	-12	144	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total adjustments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,211	1,641	1,911	611	534	-293	-2,057	-3,245	-4,592	-6,202	478	-299	780	3,990	425	2,196	4,050	0	0	0
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-14,972	-8,784	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-63,192	-52,919	-50,515	-46,796	-41,423	-26,802	0	0	0	-	-	-	-	-	-	0	0	0	-	-18,084	-16,591	-19,620	-18,723	-18,862	-18,608	-18,408	-18,555	-20,409	-20,393	-17,719	-16,697	0	0	0
Cash flows from investing activities:
Purchase of property, plant and equipment
-	-	-	-	-	61	64	105	142	190	187	146	95	3	0	0	0	-	-	-	-	-	49	63	63	37	118	146	140	146	59	0	0	0
Deferred public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Stockholder contribution
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Proceeds from issuance of Series C preference shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Sale of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Capitalized intellectual properties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Loan to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net cash used in investing activities
-	-	-	-	-	-47	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-49	-63	-63	-37	-118	-146	-140	-146	-59	0	0	0
Cash flows from financing activities:
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	25,388	25,480	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants exercised
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net proceeds from employee stock purchase plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	31	31	41	41	15	15	15	15	34	34	30	30	12	13	27	0	0	0
Net proceeds from ATM facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	1,491	1,591	4,672	4,617	3,126	3,026	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from equity line
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	203	672	1,162	1,162	959	490	0	0	0	-	-	-	-	-	-	-	-
Net proceeds from sale of unregistered common stock - private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,587	8,587	8,587	0	0	0
Proceeds from issuance of common stock, net of issuance costs
0	-	-	-	-	94,150	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,239	18,284	0	0	0	0	0	0
Royalty monetization
-	-	-	-	-	44,525	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	0	0	0	0
Proceeds from exercise of options
1,533	2,729	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75	75	0	0	0	0	0	0
Payments of principal on borrowings
-	-	-	-	-	-	-	-	-	3,055	2,889	3,096	2,623	2,157	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from bridge financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Net cash provided by financing activities
65,307	23,504	22,263	22,427	1,797	139,182	0	0	0	-	-	-	-	-	-	0	0	0	-	38,024	5,694	4,148	3,579	1,023	19,456	19,408	19,404	19,246	18,590	17,091	17,105	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-1,399	-2,087	-2,161	-742	-2,951	-1,679	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
176	-32,042	-30,936	-25,506	-42,577	110,654	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	7,146	7,612	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	646	169	503	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	56,348	17,731	24,811	-7,318	-6,293	16,471	17,206	16,257	19,875	-10,933	-15,515	-15,193	-17,902	785	963	731	-1,309	-1,943	-774	349	0	0	0
Supplemental disclosures of cash and non-cash activities:
Right of use assets and lease obligations recorded upon amended lease agreements
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	0	0	0	0	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	329	450	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	22	43	48	35	26	8	11	23	25	19	14	2	12	12	26	26	20	0	0	0
Conversion of convertible preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Warrants issued in connection with registered direct offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Warrants issued in connection with unregistered common stock private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,832	4,832	4,832	0	0	0
Settlement of debt with Series B preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Accrued expenses settled with Series B preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Deemed dividend - warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Accretion of fair value of beneficial charge on preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Conversion of convertible preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Issuance of restricted stock units to settle accrued bonus
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	584	584	584	0	0	0